Pharmaceuticals can interact with the CTZ in several ways, either triggering or inhibiting its function. Antiemetic drugs such as 5-HT3 antagonists (e.g., ondansetron) and dopamine antagonists (e.g., metoclopramide) are designed to block the receptors in the CTZ that mediate nausea and vomiting. Conversely, some drugs, especially those used in cancer treatment, may activate the CTZ and cause significant emetic side effects. Thus, the CTZ is a critical target for both the development and management of drug-induced emesis.
